BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 37381714)

  • 21. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
    Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
    Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy.
    Liu ZD; Shi YH; Xu QC; Zhao GY; Zhu YQ; Li FX; Ma MJ; Ye JY; Huang XT; Wang XY; Xu X; Wang JQ; Zhao W; Yin XY
    Cancer Lett; 2024 Mar; 585():216640. PubMed ID: 38290659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
    Yao J; Li Z; Wang X; Xu P; Zhao L; Qian J
    Acta Biochim Biophys Sin (Shanghai); 2016 Feb; 48(2):202-8. PubMed ID: 26758190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Wang Z; Chen Y; Lin Y; Wang X; Cui X; Zhang Z; Xian G; Qin C
    Int J Oncol; 2017 Oct; 51(4):1239-1248. PubMed ID: 28849150
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction.
    Jin X; Pan Y; Wang L; Ma T; Zhang L; Tang AH; Billadeau DD; Wu H; Huang H
    Cancer Res; 2017 Aug; 77(16):4328-4341. PubMed ID: 28720574
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
    Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
    BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
    Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
    Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma.
    Wang L; Wang F; Na L; Yu J; Huang L; Meng ZQ; Chen Z; Chen H; Ming LL; Hua YQ
    Cancer Biomark; 2018; 22(1):169-174. PubMed ID: 29526843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
    Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
    Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2.
    An Y; Cai B; Chen J; Lv N; Yao J; Xue X; Tu M; Tang D; Wei J; Jiang K; Wu J; Li Q; Gao W; Miao Y
    Cancer Lett; 2013 Feb; 329(2):228-35. PubMed ID: 23178452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
    Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
    Giovannetti E; Funel N; Peters GJ; Del Chiaro M; Erozenci LA; Vasile E; Leon LG; Pollina LE; Groen A; Falcone A; Danesi R; Campani D; Verheul HM; Boggi U
    Cancer Res; 2010 Jun; 70(11):4528-38. PubMed ID: 20460539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
    Gordon ER; Wright CA; James M; Cooper SJ
    BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress.
    She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J
    J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting CRABP-II overcomes pancreatic cancer drug resistance by reversing lipid raft cholesterol accumulation and AKT survival signaling.
    Yu S; Wang L; Che D; Zhang M; Li M; Naito M; Xin W; Zhou L
    J Exp Clin Cancer Res; 2022 Mar; 41(1):88. PubMed ID: 35260193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
    Song WF; Wang L; Huang WY; Cai X; Cui JJ; Wang LW
    Asian Pac J Cancer Prev; 2013; 14(12):7529-36. PubMed ID: 24460329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic ductal adenocarcinoma cells regulated the gemcitabine-resistance function of CAFs by LINC00460.
    Zhu XX; Li JH; Ni X; Wu X; Hou X; Li YX; Li SJ; Zhao W; Yin XY
    Cancer Sci; 2022 Nov; 113(11):3735-3750. PubMed ID: 36047966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
    McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
    Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.